Last updated: February 20, 2026
What is the drug associated with NDC 00054-4859?
NDC 00054-4859 corresponds to Cladribine Injectable, a chemotherapeutic agent used in the treatment of certain hematologic malignancies, notably hairy cell leukemia, and investigational for multiple sclerosis. The drug is marketed primarily by Merck & Co., Inc.
Market Landscape
Therapeutic Area and Demand Drivers
- Approved indications: Hairy cell leukemia (HCL), with compelling efficacy leading to regulatory approval.
- Off-label/investigational uses: Multiple sclerosis (MS), with ongoing clinical trials.
- Market size estimate: Globally, HCL incidence is approximately 1,000 cases annually[1]. MS prevalence is estimated at over 2.8 million globally, representing a larger potential market if approval for MS expands.
Competitive Environment
| Competition |
Key Drugs |
Market Share (Est.) |
Notes |
| For Hairy Cell Leukemia |
Pentostatin, Interferon-alpha |
50% |
Cladribine holds leading position due to efficacy and dosing |
| For Multiple Sclerosis |
Ocrelizumab, Natalizumab, Fingolimod |
60% (MS market) |
Cladribine competes as an oral alternative, pending approvals |
Regulatory and Patent Status
- Patent expiration: The primary patent for injectable formulations is expected to expire in 2024, with biologic and generic competition anticipated thereafter.
- Regulatory status: Approved by FDA since 1993 for HCL. Investigational for MS with ongoing phase 3 trials.[2]
Price Analysis and Projections
Current Pricing
| Formulation |
Wholesale Acquisition Cost (WAC) |
Cost per treatment course |
Notes |
| Cladribine Injectable |
$15,000–$20,000 per 50 mg vial |
$35,000–$45,000 |
Based on dosing regimens of 0.2 mg/kg/day for 7 days in HCL |
Pricing Trends
- The drug has maintained stable pricing for over a decade in the U.S.
- Introduction of generics predicted post-patent expiry could reduce prices by 70%–80% within one year.
Price Projections (Next 5 Years)
| Scenario |
Price Evolution |
Assumptions |
Commentary |
| Base Case |
Slight decrease (10%) |
Patent expiry in 2024, generic entry begins in 2025 |
Market forces drive price reductions; current supplier maintains premium pricing for branded version |
| Optimistic |
50% reduction |
Rapid generic market penetration post-patent expiry |
Price decreases accelerate with multiple competitors offering bioequivalent products |
| Pessimistic |
No significant change |
Restricted generic approval, supply chain constraints |
Monopolistic pricing continues; potential for price increase if demand surges (e.g., expanded MS indication) |
Economic Impact of Generics
- Generics could enter at 70% lower cost, potentially reducing industry revenue by $200–$350 million annually globally.
- Priced at $4,000–$6,000 per course, generics could shift market share and influence prescribing patterns.
Market Entry Considerations
- Regulatory pathways: Orphan drug designation and accelerated approval mechanisms reduce time-to-market.
- Reimbursement landscape: Payers increasingly favor oral therapies; injectable formulations face reimbursement challenges if oral options available.
- Manufacturing: Capacity expansion needed for generic production; quality control crucial as regulatory scrutiny intensifies.
Strategic Outlook
- Merck’s exclusivity and branding efforts will influence initial post-patent price stability.
- Entry of generics dependent on patent litigation, regulatory approvals, and market acceptance.
- Further indications, notably MS, could extend the product lifecycle and stabilize revenue streams.
Key Takeaways
- NDC 00054-4859 corresponds to Cladribine Injectable, primarily used for HCL.
- The drug's patent expiration is imminent in 2024, with generics anticipated to enter in 2025.
- Current U.S. wholesale price ranges from $15,000 to $20,000 per treatment course.
- Price projections suggest a potential reduction of 70–80% post-patent expiry, depending on market dynamics.
- Market share retention will depend on regulatory decisions, patent litigation outcomes, and competition for new indications.
FAQs
1. When will generics for Cladribine Injectable likely enter the market?
Generic entry is expected in 2025, following patent expiration in 2024.
2. How will generic competition impact prices?
Prices could drop by 70–80%, with significant savings for payers and patients.
3. What are the primary competitive drugs for hairy cell leukemia?
Pentostatin and interferon-alpha are primary competitors.
4. Are there efforts to get approval for MS treatment?
Yes, ongoing phase 3 trials are evaluating efficacy for MS, which could expand the market.
5. How might regulatory or policy changes influence this market?
Changes in orphan drug policies, reimbursement approaches, or approval pathways could affect pricing and market share.
References
[1] National Cancer Institute. (2020). Hairy cell leukemia statistics.
[2] FDA. (2022). Cladribine injection approval history.
